Rogóz Zofia, Skuza Grazyna
Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 31-343 Kraków, Poland.
Pharmacol Rep. 2006 Jul-Aug;58(4):493-500.
The aim of the present study was to examine the effect of combined treatment of male Wistar rats with pramipexole and fluoxetine or sertraline in the forced swimming test. The obtained results showed that co-treatment with pramipexole (0.1 mg/kg) and fluoxetine (10 mg/kg) or sertraline (5 mg/kg) (in doses inactive per se) exhibited antidepressant-like activity in the forced swimming test. Sulpiride (a dopamine D(2/3) receptor antagonist) and WAY 100635 (a 5-HT(1A) receptor antagonist), either being ineffective in the forced swimming test, inhibited the antidepressant-like effect induced by co-administration of pramipexole and fluoxetine or sertraline. However, SCH 23390 (a dopamine D(1) receptor antagonist) only partly did not alter the effect of pramipexole given jointly with antidepressant drugs; on the other hand, S 33084 (a dopamine D(3) receptor antagonist) only partly decreased (in a statistically insignificant manner) that effect. Moreover, progesterone and BD 1047 (a sigma(1) receptor antagonist) counteracted the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine). In that test, active behavior did not reflect the increases in general activity, since combined administration of pramipexole and fluoxetine or sertraline failed to enhance the locomotor activity of rats. None of the tested drugs (SCH 23390, sulpiride, S 33084, WAY 100635, BD 1047 and progesterone) - alone or in combination with pramipexole and fluoxetine or sertraline - changed locomotor activity. The results described in the present paper indicate that co-administration of pramipexole and fluoxetine or sertraline may induce a more pronounced antidepressive activity than does treatment with pramipexole alone, and that in addition to other mechanisms, dopamine D(2/3) and 5-HT(1A) receptors may contribute to the antidepressant-like activity of pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Moreover, sigma(1) receptors may constitute one of the possible mechanisms by which co-administration of pramipexole and sertraline induces antidepressant-like activity in that test.
本研究的目的是在强迫游泳试验中检验普拉克索与氟西汀或舍曲林联合治疗雄性Wistar大鼠的效果。所得结果表明,普拉克索(0.1毫克/千克)与氟西汀(10毫克/千克)或舍曲林(5毫克/千克)(本身无活性的剂量)联合治疗在强迫游泳试验中表现出抗抑郁样活性。舒必利(一种多巴胺D(2/3)受体拮抗剂)和WAY 100635(一种5-HT(1A)受体拮抗剂)在强迫游泳试验中均无效,但能抑制普拉克索与氟西汀或舍曲林联合给药诱导的抗抑郁样效应。然而,SCH 23390(一种多巴胺D(1)受体拮抗剂)仅部分未改变普拉克索与抗抑郁药物联合给药的效果;另一方面,S 33084(一种多巴胺D(3)受体拮抗剂)仅部分降低(在统计学上无显著意义)该效果。此外,孕酮和BD 1047(一种sigma(1)受体拮抗剂)抵消了普拉克索与舍曲林联合给药诱导的抗抑郁样效应(但未抵消普拉克索与氟西汀联合给药诱导的效应)。在该试验中,主动行为并未反映出总体活动的增加,因为普拉克索与氟西汀或舍曲林联合给药未能增强大鼠的运动活性。所测试的药物(SCH 23390、舒必利、S 33084、WAY 100635、BD 1047和孕酮)单独或与普拉克索和氟西汀或舍曲林联合使用均未改变运动活性。本文所述结果表明,普拉克索与氟西汀或舍曲林联合给药可能比单独使用普拉克索诱导出更显著的抗抑郁活性,并且除其他机制外,多巴胺D(2/3)和5-HT(1A)受体可能在大鼠强迫游泳试验中对普拉克索与氟西汀或舍曲林的抗抑郁样活性起作用。此外,sigma(1)受体可能是普拉克索与舍曲林联合给药在该试验中诱导抗抑郁样活性的可能机制之一。